Bio-Rad Laboratories Key Executives
This section highlights Bio-Rad Laboratories's key executives, including their titles and compensation details.
Find Contacts at Bio-Rad Laboratories
(Showing 0 of )
Bio-Rad Laboratories Earnings
This section highlights Bio-Rad Laboratories's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-13 | $2.86 | $2.90 |
| Read Transcript | Q3 | 2024 | 2024-10-30 | $1.28 | $2.01 |
| Read Transcript | Q2 | 2024 | 2024-08-01 | $2.12 | $3.11 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $2.15 | $2.29 |
| Read Transcript | Q4 | 2023 | 2024-02-15 | $2.93 | $3.10 |
| Read Transcript | Q3 | 2023 | 2023-10-26 | $2.87 | $2.33 |
| Read Transcript | Q2 | 2023 | 2023-08-03 | $2.55 | $3.00 |
| Read Transcript | Q1 | 2023 | 2023-05-04 | $3.24 | $3.34 |
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
$234.75
Stock Price
$6.59B
Market Cap
950
Employees
Hercules, CA
Location
Financial Statements
Access annual & quarterly financial statements for Bio-Rad Laboratories, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B |
| Cost of Revenue | $1.19B | $1.24B | $1.23B | $1.28B | $1.11B |
| Gross Profit | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B |
| Gross Profit Ratio | 53.73% | 53.40% | 55.93% | 56.10% | 56.48% |
| Research and Development Expenses | $295.90M | $247.43M | $256.89M | $271.66M | $226.60M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $814.00M | $824.22M | $827.83M | $879.57M | $800.27M |
| Other Expenses | $- | $- | $44.57M | $26.77M | $24.49M |
| Operating Expenses | $1.11B | $1.05B | $1.08B | $1.15B | $1.03B |
| Cost and Expenses | $2.30B | $2.29B | $2.32B | $2.43B | $2.13B |
| Interest Income | $82.00M | $100.90M | $58.00M | $18.90M | $18.20M |
| Interest Expense | $48.90M | $49.44M | $38.11M | $1.55M | $21.86M |
| Depreciation and Amortization | $151.60M | $145.90M | $177.20M | $176.90M | $175.20M |
| EBITDA | $-2.14B | $-608.26M | $-4.49B | $5.63B | $5.10B |
| EBITDA Ratio | -83.46% | -22.77% | -160.00% | 22.24% | 22.53% |
| Operating Income | $269.00M | $337.80M | $482.62M | $489.43M | $410.96M |
| Operating Income Ratio | 10.48% | 12.65% | 17.22% | 16.75% | 16.14% |
| Total Other Income Expenses Net | $-2.61B | $-1.19B | $-5.19B | $4.95B | $4.49B |
| Income Before Tax | $-2.34B | $-850.10M | $-4.70B | $5.44B | $4.91B |
| Income Before Tax Ratio | -91.27% | -31.82% | -167.87% | 186.08% | 192.79% |
| Income Tax Expense | $-498.30M | $-212.78M | $-1.08B | $1.19B | $1.10B |
| Net Income | $-1.84B | $-637.32M | $-3.63B | $4.25B | $3.81B |
| Net Income Ratio | -71.86% | -23.86% | -129.45% | 145.57% | 149.83% |
| EPS | $-65.36 | $-21.82 | $-121.79 | $142.61 | $127.86 |
| EPS Diluted | $-65.36 | $-21.82 | $-121.79 | $140.83 | $126.20 |
| Weighted Average Shares Outstanding | 28.21M | 29.21M | 29.79M | 29.83M | 29.77M |
| Weighted Average Shares Outstanding Diluted | 28.21M | 29.21M | 29.79M | 30.21M | 30.16M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $667.50M | $649.73M | $638.48M | $610.82M | $681.18M | $632.12M | $681.11M | $676.84M | $730.29M | $680.80M | $691.10M | $700.06M | $732.77M | $747.05M | $715.93M | $726.80M | $789.84M | $647.26M | $536.88M | $571.64M |
| Cost of Revenue | $325.50M | $293.83M | $282.76M | $284.35M | $315.28M | $296.44M | $318.63M | $314.43M | $333.19M | $307.01M | $295.12M | $296.50M | $331.77M | $309.61M | $314.33M | $326.17M | $329.68M | $279.95M | $243.89M | $254.28M |
| Gross Profit | $342.00M | $355.90M | $355.72M | $326.47M | $365.90M | $335.68M | $362.48M | $362.42M | $397.10M | $373.79M | $395.98M | $403.56M | $401.00M | $437.44M | $401.60M | $400.63M | $460.15M | $367.31M | $292.99M | $317.37M |
| Gross Profit Ratio | 51.24% | 54.80% | 55.70% | 53.40% | 53.70% | 53.10% | 53.20% | 53.50% | 54.40% | 54.90% | 57.30% | 57.60% | 54.70% | 58.60% | 56.10% | 55.10% | 58.26% | 56.75% | 54.57% | 55.52% |
| Research and Development Expenses | $79.60M | $91.00M | $59.30M | $63.98M | $62.21M | $43.53M | $65.04M | $74.95M | $66.20M | $69.95M | $67.03M | $62.54M | $69.87M | $64.48M | $63.39M | $73.91M | $65.77M | $59.55M | $51.98M | $49.30M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $193.69M | $- | $- | $193.69M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $25.46M | $- | $- | $- |
| Selling General and Administrative Expenses | $204.00M | $200.44M | $196.12M | $210.48M | $205.90M | $201.20M | $207.82M | $225.55M | $212.23M | $211.05M | $208.73M | $197.59M | $224.15M | $216.15M | $213.43M | $225.85M | $219.15M | $198.16M | $189.26M | $193.69M |
| Other Expenses | $- | $- | $1.60M | $700.00K | $-65.00K | $20.45M | $16.49M | $50.43M | $2.21M | $3.06M | $6.71M | $32.60M | $10.04M | $-579.00K | $-96.00K | $17.41M | $2.97M | $1.01M | $17.23M | $3.27M |
| Operating Expenses | $283.60M | $291.44M | $255.42M | $274.46M | $268.11M | $244.73M | $272.87M | $300.50M | $278.43M | $281.00M | $275.76M | $260.14M | $294.02M | $280.63M | $276.82M | $299.76M | $284.91M | $257.71M | $241.25M | $243.00M |
| Cost and Expenses | $609.10M | $585.26M | $538.18M | $558.81M | $583.39M | $541.17M | $591.49M | $614.93M | $611.62M | $588.00M | $570.88M | $556.64M | $625.79M | $590.25M | $591.15M | $625.93M | $614.60M | $537.66M | $485.14M | $497.27M |
| Interest Income | $15.90M | $15.50M | $16.60M | $34.00M | $16.80M | $17.30M | $16.50M | $50.30M | $12.30M | $8.00M | $5.50M | $- | $200.00K | $426.00K | $700.00K | $- | $3.60M | $1.80M | $10.00M | $2.80M |
| Interest Expense | $12.19M | $12.17M | $12.26M | $12.28M | $12.36M | $12.40M | $12.34M | $12.34M | $11.68M | $11.66M | $10.72M | $4.05M | $364.00K | $- | $363.00K | $398.00K | $4.70M | $5.73M | $5.74M | $5.69M |
| Depreciation and Amortization | $- | $49.10M | $46.60M | $47.80M | $53.00M | $48.10M | $57.60M | $45.60M | $50.07M | $42.50M | $42.60M | $42.00M | $43.70M | $43.40M | $43.50M | $42.50M | $36.19M | $15.01M | $53.34M | $33.59M |
| EBITDA | $58.40M | $922.89M | $-2.73B | $551.15M | $493.75M | $197.60M | $-1.43B | $142.77M | $1.15B | $-155.00M | $-1.17B | $-4.32B | $-1.99B | $5.07B | $1.20B | $1.34B | $1.13B | $1.73B | $1.30B | $947.59M |
| EBITDA Ratio | 8.75% | 142.04% | -427.00% | 90.00% | 72.00% | 31.00% | -210.00% | 21.00% | 22.02% | 18.89% | 23.08% | -618.00% | 20.57% | 25.42% | 22.12% | 20.78% | 27.15% | 19.41% | 22.78% | 19.46% |
| Operating Income | $58.40M | $64.47M | $100.30M | $52.01M | $97.79M | $90.95M | $89.62M | $112.34M | $118.67M | $92.80M | $120.22M | $143.42M | $106.98M | $156.80M | $124.78M | $100.86M | $175.24M | $109.60M | $51.74M | $74.37M |
| Operating Income Ratio | 8.75% | 9.92% | 15.71% | 8.51% | 14.36% | 14.39% | 13.16% | 16.60% | 16.25% | 13.63% | 17.40% | 20.49% | 14.60% | 20.99% | 17.43% | 13.88% | 22.19% | 16.93% | 9.64% | 13.01% |
| Total Other Income Expenses Net | $-967.30M | $797.15M | $-2.89B | $439.07M | $330.60M | $46.15M | $-1.59B | $22.92M | $972.61M | $-301.96M | $-1.34B | $-4.51B | $-2.15B | $4.87B | $1.03B | $1.20B | $903.29M | $1.57B | $1.19B | $824.33M |
| Income Before Tax | $-908.90M | $861.62M | $-2.79B | $491.08M | $428.39M | $137.10M | $-1.50B | $84.83M | $1.09B | $-209.17M | $-1.22B | $-4.37B | $-2.04B | $5.02B | $1.16B | $1.30B | $1.08B | $1.68B | $1.25B | $898.70M |
| Income Before Tax Ratio | -136.16% | 132.61% | -436.40% | 80.40% | 62.89% | 21.69% | -220.29% | 12.53% | 149.43% | -30.72% | -176.95% | -624.38% | -278.13% | 672.28% | 161.58% | 178.48% | 136.55% | 260.24% | 232.07% | 157.21% |
| Income Tax Expense | $-193.12M | $208.45M | $-620.79M | $107.16M | $78.68M | $30.84M | $-338.18M | $15.87M | $263.55M | $-44.94M | $-295.70M | $-1.00B | $-464.40M | $1.09B | $242.66M | $319.79M | $239.43M | $369.64M | $279.52M | $212.79M |
| Net Income | $-715.80M | $653.17M | $-2.17B | $383.92M | $349.71M | $106.26M | $-1.16B | $68.96M | $833.49M | $-164.23M | $-927.18M | $-3.37B | $-1.57B | $3.93B | $914.11M | $977.41M | $839.10M | $1.31B | $966.43M | $685.91M |
| Net Income Ratio | -107.24% | 100.53% | -339.16% | 62.85% | 51.34% | 16.81% | -170.64% | 10.19% | 114.13% | -24.12% | -134.16% | -481.33% | -214.76% | 525.81% | 127.68% | 134.48% | 106.24% | 203.14% | 180.01% | 119.99% |
| EPS | $-25.57 | $23.37 | $-76.26 | $13.46 | $12.15 | $3.65 | $-39.59 | $2.33 | $27.89 | $-5.53 | $-31.12 | $-112.58 | $-52.59 | $131.75 | $30.71 | $32.77 | $28.13 | $44.24 | $32.59 | $22.97 |
| EPS Diluted | $-25.57 | $23.34 | $-76.26 | $13.45 | $12.14 | $3.64 | $-39.59 | $2.32 | $27.78 | $-5.52 | $-31.12 | $-112.57 | $-52.59 | $129.96 | $30.32 | $32.38 | $27.81 | $43.64 | $32.15 | $22.72 |
| Weighted Average Shares Outstanding | 28.00M | 27.95M | 28.39M | 28.52M | 28.79M | 29.10M | 29.36M | 29.60M | 29.68M | 29.71M | 29.79M | 29.93M | 29.92M | 29.81M | 29.76M | 29.82M | 29.83M | 29.72M | 29.65M | 29.86M |
| Weighted Average Shares Outstanding Diluted | 28.00M | 27.98M | 28.39M | 28.54M | 28.82M | 29.22M | 29.36M | 29.75M | 29.79M | 29.73M | 29.79M | 29.93M | 29.92M | 30.22M | 30.15M | 30.19M | 30.17M | 30.13M | 30.06M | 30.20M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $- | $403.81M | $434.21M | $470.78M | $662.21M |
| Short Term Investments | $1.18B | $1.20B | $1.36B | $404.69M | $334.47M |
| Cash and Short Term Investments | $1.18B | $1.61B | $1.80B | $875.48M | $996.68M |
| Net Receivables | $- | $489.02M | $494.64M | $423.54M | $419.42M |
| Inventory | $- | $780.52M | $719.32M | $572.24M | $622.25M |
| Other Current Assets | $30.70M | $171.65M | $153.34M | $124.78M | $97.49M |
| Total Current Assets | $1.21B | $3.05B | $3.16B | $1.99B | $2.14B |
| Property Plant Equipment Net | $688.60M | $723.74M | $679.56M | $695.75M | $693.51M |
| Goodwill | $410.50M | $413.60M | $406.49M | $347.34M | $291.92M |
| Intangible Assets | $293.60M | $320.48M | $332.15M | $253.94M | $199.50M |
| Goodwill and Intangible Assets | $704.10M | $734.08M | $738.63M | $601.28M | $491.41M |
| Long Term Investments | $4.84B | $7.70B | $8.83B | $14.39B | $9.56B |
| Tax Assets | $-688.60M | $- | $1.77T | $3.06T | $2.08T |
| Other Non-Current Assets | $-586.70M | $94.85M | $-1.77T | $-3.06T | $-2.08T |
| Total Non-Current Assets | $5.65B | $9.25B | $10.34B | $15.79B | $10.83B |
| Other Assets | $2.51B | $- | $- | $- | $- |
| Total Assets | $9.36B | $12.30B | $13.50B | $17.78B | $12.97B |
| Account Payables | $122.30M | $144.62M | $135.04M | $141.94M | $139.45M |
| Short Term Debt | $42.90M | $40.87M | $36.80M | $36.92M | $38.31M |
| Tax Payables | $31.20M | $35.76M | $32.43M | $46.30M | $57.34M |
| Deferred Revenue | $- | $- | $52.21M | $50.85M | $42.47M |
| Other Current Liabilities | $271.40M | $301.55M | $312.23M | $404.92M | $353.98M |
| Total Current Liabilities | $467.80M | $522.80M | $568.71M | $680.94M | $631.54M |
| Long Term Debt | $131.40M | $1.37B | $1.36B | $186.45M | $187.43M |
| Deferred Revenue Non-Current | $- | $-9.65M | $1.77T | $-3.06B | $-2.08B |
| Deferred Tax Liabilities Non-Current | $818.00M | $1.48B | $1.77B | $3.06B | $2.08B |
| Other Non-Current Liabilities | $1.38B | $185.47M | $185.81M | $3.25B | $196.93M |
| Total Non-Current Liabilities | $2.33B | $3.04B | $3.32B | $3.43B | $2.46B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $2.79B | $3.56B | $3.89B | $4.11B | $3.09B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $- | $3.00K | $3.00K | $3.00K | $3.00K |
| Retained Earnings | $7.42B | $9.26B | $9.90B | $13.51B | $9.27B |
| Accumulated Other Comprehensive Income Loss | $-538.20M | $-336.04M | $-466.82M | $-175.55M | $282.46M |
| Other Total Stockholders Equity | $-308.90M | $-183.46M | $183.87M | $335.44M | $329.47M |
| Total Stockholders Equity | $6.57B | $8.74B | $9.62B | $13.67B | $9.88B |
| Total Equity | $6.57B | $8.74B | $9.62B | $13.67B | $9.88B |
| Total Liabilities and Stockholders Equity | $9.36B | $12.30B | $13.50B | $17.78B | $12.97B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $9.36B | $12.30B | $13.50B | $17.78B | $12.97B |
| Total Investments | $6.02B | $8.90B | $8.84B | $14.79B | $9.90B |
| Total Debt | $174.30M | $1.41B | $1.20B | $11.00M | $14.06M |
| Net Debt | $174.30M | $1.00B | $763.97M | $-459.78M | $-648.15M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $488.10M | $411.75M | $407.30M | $433.33M | $403.97M | $457.85M | $390.00M | $464.14M | $434.21M | $517.94M | $596.58M | $802.32M | $470.78M | $859.90M | $732.84M | $673.47M | $662.21M | $840.33M | $607.58M | $603.55M |
| Short Term Investments | $1.18B | $1.21B | $1.21B | $1.22B | $1.21B | $1.31B | $1.34B | $1.39B | $1.36B | $1.34B | $1.38B | $1.28B | $404.69M | $482.76M | $434.12M | $351.96M | $334.47M | $319.66M | $429.79M | $438.71M |
| Cash and Short Term Investments | $1.66B | $1.62B | $1.62B | $1.65B | $1.61B | $1.76B | $1.73B | $1.86B | $1.80B | $1.86B | $1.97B | $2.08B | $875.48M | $1.34B | $1.17B | $1.03B | $996.68M | $1.16B | $1.04B | $1.04B |
| Net Receivables | $452.50M | $461.94M | $455.31M | $459.61M | $500.92M | $457.40M | $491.57M | $498.27M | $494.64M | $432.30M | $450.32M | $464.11M | $423.54M | $417.71M | $399.31M | $408.14M | $419.42M | $402.24M | $369.77M | $380.48M |
| Inventory | $760.00M | $804.28M | $803.69M | $783.37M | $780.52M | $775.82M | $776.60M | $752.94M | $719.32M | $685.85M | $657.13M | $605.49M | $572.24M | $588.91M | $598.99M | $605.16M | $622.25M | $640.23M | $628.40M | $557.03M |
| Other Current Assets | $153.30M | $166.95M | $175.21M | $166.67M | $154.04M | $154.56M | $148.00M | $174.59M | $153.34M | $171.88M | $174.58M | $160.34M | $124.78M | $122.56M | $129.40M | $142.16M | $97.49M | $117.64M | $102.61M | $108.38M |
| Total Current Assets | $3.03B | $3.06B | $3.06B | $3.06B | $3.05B | $3.15B | $3.14B | $3.28B | $3.16B | $3.14B | $3.25B | $3.30B | $1.99B | $2.47B | $2.29B | $2.18B | $2.14B | $2.32B | $2.13B | $2.08B |
| Property Plant Equipment Net | $688.60M | $719.17M | $715.24M | $711.28M | $723.74M | $711.40M | $687.93M | $680.55M | $679.56M | $632.70M | $656.47M | $684.20M | $695.75M | $680.84M | $672.23M | $678.94M | $693.51M | $677.60M | $679.02M | $686.66M |
| Goodwill | $410.50M | $415.10M | $412.12M | $412.82M | $413.60M | $406.95M | $411.52M | $407.76M | $406.49M | $399.59M | $347.32M | $345.73M | $347.34M | $291.92M | $291.92M | $291.92M | $291.92M | $291.92M | $291.50M | $264.13M |
| Intangible Assets | $293.60M | $307.30M | $307.10M | $313.60M | $320.50M | $314.19M | $328.71M | $327.83M | $332.15M | $325.08M | $239.75M | $247.14M | $253.94M | $177.07M | $184.85M | $191.76M | $199.50M | $205.31M | $211.37M | $138.32M |
| Goodwill and Intangible Assets | $704.10M | $722.40M | $719.20M | $726.40M | $734.10M | $721.14M | $740.23M | $735.59M | $738.63M | $724.66M | $587.07M | $592.87M | $601.28M | $468.99M | $476.77M | $483.68M | $491.41M | $497.22M | $502.87M | $402.45M |
| Long Term Investments | $4.84B | $6.00B | $5.10B | $8.02B | $7.70B | $7.22B | $7.31B | $8.88B | $8.83B | $7.46B | $8.09B | $9.69B | $14.39B | $16.23B | $11.58B | $10.50B | $9.56B | $8.44B | $6.70B | $5.43B |
| Tax Assets | $- | $- | $878.46M | $1.54B | $1.48T | $1.37B | $1.40B | $1.77T | $- | $1.48T | $1.61T | $2.00T | $- | $3.57T | $2.54T | $2.31T | $- | $1.84T | $1.46T | $1.16T |
| Other Non-Current Assets | $101.90M | $103.62M | $-780.68M | $-1.45B | $-1.48T | $-1.27B | $-1.30B | $-1.77T | $94.60M | $-1.48T | $-1.61T | $-2.00T | $102.67M | $-3.57T | $-2.54T | $-2.31T | $86.72M | $-1.84T | $-1.46T | $-1.16T |
| Total Non-Current Assets | $6.33B | $7.55B | $6.63B | $9.55B | $9.25B | $8.75B | $8.84B | $10.39B | $10.34B | $8.92B | $9.43B | $11.07B | $15.79B | $17.49B | $12.83B | $11.76B | $10.83B | $9.70B | $7.96B | $6.60B |
| Other Assets | $- | $25.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $9.36B | $10.60B | $9.69B | $12.61B | $12.30B | $11.90B | $11.98B | $13.67B | $13.50B | $12.06B | $12.68B | $14.37B | $17.78B | $19.95B | $15.12B | $13.93B | $12.97B | $12.02B | $10.10B | $8.68B |
| Account Payables | $122.30M | $122.19M | $126.69M | $102.75M | $144.62M | $111.86M | $149.53M | $160.98M | $135.04M | $142.75M | $158.26M | $160.65M | $141.94M | $136.40M | $133.46M | $138.49M | $139.45M | $132.99M | $130.91M | $118.22M |
| Short Term Debt | $42.90M | $42.83M | $42.00M | $40.52M | $40.87M | $39.59M | $37.02M | $36.67M | $36.80M | $34.44M | $36.23M | $37.74M | $36.92M | $37.76M | $37.31M | $40.94M | $38.31M | $460.99M | $460.94M | $461.25M |
| Tax Payables | $31.20M | $43.62M | $35.90M | $33.96M | $35.76B | $103.98M | $74.48M | $50.87M | $32.43M | $29.27M | $25.91M | $54.31M | $46.30M | $54.05M | $52.42M | $89.07M | $57.34M | $41.65M | $32.02M | $32.30M |
| Deferred Revenue | $- | $- | $-126.69M | $33.96M | $35.76B | $-111.86M | $74.48M | $- | $52.21M | $1.48T | $25.91M | $- | $50.85M | $54.05M | $52.42M | $89.07M | $42.47M | $41.65M | $32.02M | $32.30M |
| Other Current Liabilities | $271.40M | $289.30M | $282.38M | $288.92M | $-35.42B | $302.75M | $320.95M | $341.11M | $312.23M | $364.21M | $393.31M | $395.63M | $404.92M | $421.71M | $363.87M | $341.39M | $353.98M | $351.03M | $303.03M | $257.49M |
| Total Current Liabilities | $467.80M | $497.94M | $486.96M | $466.15M | $522.80M | $558.18M | $581.98M | $589.62M | $568.71M | $570.68M | $613.71M | $648.33M | $680.94M | $649.92M | $587.05M | $609.89M | $631.54M | $986.66M | $926.89M | $869.25M |
| Long Term Debt | $- | $1.34B | $1.35B | $1.36B | $1.36B | $1.37B | $1.36B | $1.36B | $1.36B | $1.35B | $1.37B | $1.38B | $186.45M | $198.06M | $185.49M | $190.13M | $187.43M | $184.34M | $196.44M | $198.66M |
| Deferred Revenue Non-Current | $- | $-38.00K | $160.38M | $169.31M | $175.08M | $-1.37B | $-1.40B | $- | $1.77T | $- | $-1.61B | $- | $3.06T | $-3.57B | $-2.54B | $-2.31B | $2.08T | $-1.84B | $-1.46B | $-1.16B |
| Deferred Tax Liabilities Non-Current | $- | $1.08B | $878.46M | $1.54B | $1.48B | $1.37B | $1.40B | $1.77B | $1.77B | $1.48B | $1.61B | $2.00B | $3.06B | $3.57B | $2.54B | $2.31B | $2.08B | $1.84B | $1.46B | $1.16B |
| Other Non-Current Liabilities | $2.33B | $197.59M | $193.54M | $192.42M | $195.11M | $186.12M | $192.39M | $189.25M | $185.81M | $194.89M | $166.62M | $169.69M | $3.24B | $203.69M | $207.94M | $217.97M | $196.93M | $182.13M | $163.92M | $162.26M |
| Total Non-Current Liabilities | $2.33B | $2.62B | $2.42B | $3.09B | $3.04B | $2.92B | $2.95B | $3.31B | $3.32B | $3.03B | $3.15B | $3.54B | $3.43B | $3.97B | $2.94B | $2.71B | $2.46B | $2.21B | $1.82B | $1.52B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $2.79B | $3.12B | $2.91B | $3.56B | $3.56B | $3.48B | $3.53B | $3.90B | $3.89B | $3.60B | $3.76B | $4.19B | $4.11B | $4.62B | $3.52B | $3.32B | $3.09B | $3.20B | $2.74B | $2.39B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K |
| Retained Earnings | $- | $8.13B | $7.48B | $9.64B | $9.26B | $8.91B | $8.80B | $9.97B | $9.90B | $9.05B | $9.21B | $10.14B | $13.51B | $15.08B | $11.16B | $10.25B | $9.27B | $8.43B | $7.12B | $6.16B |
| Accumulated Other Comprehensive Income Loss | $- | $-315.27M | $-451.36M | $-425.97M | $-336.04M | $-497.56M | $-372.86M | $-408.35M | $-466.82M | $-845.21M | $-533.39M | $-307.86M | $-175.55M | $-63.04M | $125.17M | $68.43M | $282.46M | $83.97M | $-61.14M | $-148.96M |
| Other Total Stockholders Equity | $6.57B | $-329.10M | $-248.91M | $-167.44M | $-183.46M | $2.83M | $15.09M | $205.11M | $183.87M | $252.29M | $245.52M | $353.14M | $335.44M | $314.56M | $310.24M | $295.20M | $329.47M | $312.25M | $291.45M | $285.34M |
| Total Stockholders Equity | $6.57B | $7.49B | $6.78B | $9.05B | $8.74B | $8.42B | $8.45B | $9.76B | $9.62B | $8.45B | $8.92B | $10.18B | $13.67B | $15.33B | $11.59B | $10.61B | $9.88B | $8.83B | $7.35B | $6.29B |
| Total Equity | $6.57B | $7.49B | $6.78B | $9.05B | $8.74B | $8.42B | $8.45B | $9.76B | $9.62B | $8.45B | $8.92B | $10.18B | $13.67B | $15.33B | $11.59B | $10.61B | $9.88B | $8.83B | $7.35B | $6.29B |
| Total Liabilities and Stockholders Equity | $9.36B | $10.60B | $9.69B | $12.61B | $12.30B | $11.90B | $11.98B | $13.67B | $13.50B | $12.06B | $12.68B | $14.37B | $17.78B | $19.95B | $15.12B | $13.93B | $12.97B | $12.02B | $10.10B | $8.68B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $9.36B | $10.60B | $9.69B | $12.61B | $12.30B | $11.90B | $11.98B | $13.67B | $13.50B | $12.06B | $12.68B | $14.37B | $17.78B | $19.95B | $15.12B | $13.93B | $12.97B | $12.02B | $10.10B | $8.68B |
| Total Investments | $6.02B | $7.21B | $6.31B | $9.24B | $8.91B | $8.52B | $8.65B | $10.27B | $8.84B | $8.80B | $9.46B | $10.97B | $14.79B | $16.71B | $12.01B | $10.85B | $9.89B | $8.75B | $7.13B | $5.87B |
| Total Debt | $1.20M | $1.39B | $1.39B | $1.40B | $1.41B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $11.00M | $12.38M | $12.52M | $12.64M | $14.06M | $438.88M | $438.74M | $438.51M |
| Net Debt | $-486.90M | $977.74M | $985.40M | $966.39M | $1.00B | $741.34M | $808.86M | $734.39M | $763.97M | $679.78M | $600.83M | $394.93M | $-459.78M | $-847.52M | $-720.32M | $-660.83M | $-648.15M | $-401.45M | $-168.85M | $-165.04M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-99.40M | $-637.32M | $-3.63B | $4.25B | $3.81B |
| Depreciation and Amortization | $151.60M | $- | $137.30M | $133.80M | $138.13M |
| Deferred Income Tax | $- | $- | $-1.24B | $-51.20M | $-41.60M |
| Stock Based Compensation | $- | $61.30M | $60.90M | $51.20M | $41.60M |
| Change in Working Capital | $-620.80M | $-432.80M | $-407.04M | $13.93M | $51.68M |
| Accounts Receivables | $- | $11.40M | $-87.40M | $-20.40M | $-15.00M |
| Inventory | $- | $- | $-158.80M | $46.10M | $-52.10M |
| Accounts Payables | $-40.90M | $-51.80M | $-94.20M | $69.90M | $124.70M |
| Other Working Capital | $-579.90M | $-392.40M | $-66.64M | $-81.67M | $-5.92M |
| Other Non Cash Items | $1.02B | $1.38B | $5.27B | $-3.74B | $-3.42B |
| Net Cash Provided by Operating Activities | $455.20M | $374.94M | $194.45M | $656.52M | $575.33M |
| Investments in Property Plant and Equipment | $-165.60M | $-156.68M | $-114.16M | $-120.80M | $-98.92M |
| Acquisitions Net | $- | $2.71M | $-100.75M | $-125.52M | $-96.66M |
| Purchases of Investments | $-1.28B | $-689.04M | $-2.06B | $-1.31B | $-345.11M |
| Sales Maturities of Investments | $1.31B | $361.28M | $1.07B | $766.90M | $368.06M |
| Other Investing Activities | $-23.30M | $501.94M | $1.52M | $52.00K | $112.38M |
| Net Cash Used for Investing Activities | $-160.20M | $20.21M | $-1.21B | $-784.44M | $-60.25M |
| Debt Repayment | $-400.00K | $-467.00K | $1.19B | $-3.02M | $-426.94M |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-203.60M | $-428.73M | $-215.68M | $-50.00M | $-100.00M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-14.80M | $3.55M | $3.54M | $-2.41M | $3.90M |
| Net Cash Used Provided by Financing Activities | $-218.80M | $-425.65M | $973.58M | $-55.43M | $-523.04M |
| Effect of Forex Changes on Cash | $9.20M | $321.00K | $2.98M | $-12.64M | $12.43M |
| Net Change in Cash | $85.40M | $-30.18M | $-36.59M | $-195.98M | $4.46M |
| Cash at End of Period | $489.80M | $404.37M | $434.54M | $471.13M | $667.12M |
| Cash at Beginning of Period | $404.40M | $434.54M | $471.13M | $667.12M | $662.65M |
| Operating Cash Flow | $455.20M | $374.94M | $194.45M | $656.52M | $575.33M |
| Capital Expenditure | $-189.00M | $-156.68M | $-114.16M | $-120.80M | $-98.92M |
| Free Cash Flow | $266.20M | $218.26M | $80.29M | $535.72M | $476.41M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-715.80M | $653.20M | $-2.17B | $383.92M | $349.71M | $106.27M | $-1.16B | $68.96M | $833.49M | $-164.23M | $-927.18M | $-3.37B | $-1.57B | $3.93B | $914.11M | $977.41M | $839.10M | $1.31B | $966.43M | $685.91M |
| Depreciation and Amortization | $39.20M | $49.10M | $46.60M | $47.80M | $53.00M | $37.32M | $35.85M | $35.59M | $39.95M | $32.72M | $32.61M | $32.01M | $33.73M | $33.69M | $33.65M | $32.74M | $36.19M | $15.01M | $53.34M | $33.59M |
| Deferred Income Tax | $- | $166.60M | $-659.30M | $84.20M | $74.80M | $-15.90M | $-12.60M | $-13.90K | $- | $- | $- | $4.53B | $-15.00M | $-13.10M | $-11.40M | $-11.70M | $-12.30M | $-10.80M | $-8.80M | $-9.70M |
| Stock Based Compensation | $16.40M | $-30.30M | $15.00M | $15.30M | $16.20M | $15.90M | $12.60M | $16.60M | $18.10M | $15.70M | $13.60M | $13.50M | $15.00M | $13.10M | $11.40M | $11.70M | $12.30M | $10.80M | $8.80M | $9.70M |
| Change in Working Capital | $-216.00M | $220.70M | $-24.07M | $-28.32M | $-93.86M | $360.48M | $-16.27M | $-38.83M | $-63.14M | $-100.46M | $-86.85M | $-156.59M | $28.47M | $46.88M | $-3.91M | $-57.50M | $96.04M | $-9.82M | $567.00K | $-35.11M |
| Accounts Receivables | $-9.40M | $-33.00M | $-4.40M | $37.40M | $-20.20M | $26.40M | $6.60M | $-1.40M | $-42.90M | $1.30M | $1.00M | $-46.80M | $-9.60M | $-23.70M | $11.60M | $1.30M | $-5.40M | $-34.30M | $22.50M | $2.20M |
| Inventory | $24.50M | $31.20M | $-22.40M | $-8.80M | $15.40M | $-6.40M | $-25.20M | $-30.10M | $-8.20M | $-48.30M | $-66.80M | $-35.50M | $17.90M | $13.90M | $8.50M | $5.80M | $31.40M | $-3.70M | $-66.10M | $-13.70M |
| Accounts Payables | $-16.50M | $26.60M | $17.80M | $-44.40M | $20.60M | $-37.70M | $-42.90M | $8.20M | $-24.50M | $-26.60M | $-4.20M | $-38.90M | $47.50M | $56.60M | $10.30M | $-44.50M | $45.50M | $49.50M | $55.30M | $-25.60M |
| Other Working Capital | $-214.60M | $195.90M | $-15.07M | $-12.52M | $-109.66M | $378.18M | $45.23M | $-15.53M | $12.46M | $-26.86M | $-333.90M | $-35.39M | $-27.33M | $80.00K | $-34.31M | $-20.10M | $24.54M | $-21.32M | $-11.13M | $1.99M |
| Other Non Cash Items | $1.00B | $-895.69M | $3.00B | $-307.02M | $-318.80M | $-406.36M | $1.24B | $15.81M | $-737.99M | $223.78M | $-306.57M | $-1.00B | $1.65B | $-3.79B | $-800.63M | $-850.74M | $-698.89M | $-1.20B | $-937.01M | $-631.29M |
| Net Cash Provided by Operating Activities | $124.15M | $163.61M | $97.65M | $69.17M | $81.05M | $97.71M | $98.07M | $98.12M | $90.42M | $7.51M | $50.20M | $46.31M | $157.92M | $230.36M | $154.62M | $113.61M | $284.73M | $135.66M | $92.12M | $62.81M |
| Investments in Property Plant and Equipment | $-42.91M | $-40.23M | $-42.28M | $-40.18M | $-42.24M | $-44.07M | $-34.64M | $-35.73M | $-46.93M | $-24.06M | $-14.26M | $-28.90M | $-43.24M | $-34.63M | $-23.39M | $-19.55M | $-39.13M | $-19.98M | $-18.12M | $-21.69M |
| Acquisitions Net | $- | $- | $66.00K | $26.00K | $2.61M | $44.07M | $34.64M | $35.73M | $45.56M | $-100.75M | $1.47M | $-48.98M | $-125.52M | $39.00K | $1.00K | $12.00K | $84.42M | $234.00K | $-96.89M | $- |
| Purchases of Investments | $-222.94M | $-399.12M | $-248.08M | $-406.46M | $-151.50M | $-196.02M | $-137.93M | $-203.59M | $-253.09M | $-328.72M | $-517.49M | $-960.94M | $-845.01M | $-204.78M | $-180.35M | $-74.92M | $-160.45M | $-12.00M | $-74.51M | $-98.15M |
| Sales Maturities of Investments | $235.35M | $407.07M | $259.37M | $403.51M | $-238.60M | $230.52M | $200.52M | $168.84M | $230.66M | $368.61M | $388.88M | $77.88M | $459.28M | $158.02M | $103.46M | $46.13M | $49.38M | $122.58M | $88.71M | $107.38M |
| Other Investing Activities | $-39.00K | $-23.35M | $11.35M | $26.00K | $501.94M | $-44.01M | $-34.60M | $-35.73M | $-45.51M | $6.00K | $376.08M | $48.98M | $-43.24M | $-34.59M | $-23.39M | $-19.54M | $60.95M | $-19.96M | $-5.88M | $-21.65M |
| Net Cash Used for Investing Activities | $-30.54M | $-55.64M | $-30.93M | $-43.09M | $72.20M | $-9.50M | $27.98M | $-70.47M | $-69.31M | $-84.91M | $-141.41M | $-911.96M | $-554.48M | $-81.35M | $-100.28M | $-48.33M | $-50.11M | $90.85M | $-88.57M | $-12.42M |
| Debt Repayment | $-41.00K | $-123.00K | $-118.00K | $-118.00K | $-118.00K | $-118.00K | $-116.00K | $-115.00K | $-143.00K | $-113.00K | $-150.00K | $1.19B | $-1.38M | $-122.00K | $-122.00K | $-1.40M | $-425.16M | $-183.00K | $-182.00K | $-1.42M |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $4.42M | $- | $4.77M | $- | $4.18M | $6.17M | $6.35M | $4.05M | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-14.00K | $-97.84M | $-101.00M | $-4.75M | $-200.00M | $-21.32M | $-207.41M | $-4.42M | $-90.68M | $-13.43M | $-125.00M | $- | $-162.00K | $-21.81M | $-507.00K | $-50.00M | $-100.00K | $1.00K | $-6.93M | $-100.00M |
| Dividends Paid | $- | $-15.84M | $- | $-15.84M | $-85.44B | $- | $- | $-14.66M | $-47.43B | $- | $- | $-20.68B | $-35.28B | $- | $- | $-12.19B | $- | $- | $- | $- |
| Other Financing Activities | $-26.19M | $17.81M | $4.53M | $20.72M | $-502.00K | $-5.16M | $4.79M | $4.42M | $47.44B | $-8.66M | $3.82M | $20.68B | $35.29B | $-15.46M | $2.99M | $4.05M | $3.27M | $621.00K | $-2.80M | $2.80M |
| Net Cash Used Provided by Financing Activities | $-26.25M | $-95.99M | $-96.59M | $638.00K | $-200.62M | $-26.60M | $-202.74M | $4.31M | $-86.62M | $-8.77M | $-121.33M | $1.19B | $4.63M | $-15.58M | $2.87M | $-47.35M | $-421.88M | $439.00K | $-2.98M | $-98.62M |
| Effect of Forex Changes on Cash | $10.22M | $-7.51M | $3.83M | $2.66M | $-6.57M | $6.22M | $2.67M | $-2.00M | $-18.19M | $7.50M | $6.79M | $6.88M | $-1.46M | $-6.07M | $2.25M | $-7.35M | $9.27M | $6.01M | $3.12M | $-5.98M |
| Net Change in Cash | $77.61M | $4.89M | $-26.03M | $29.36M | $-53.96M | $67.83M | $-74.02M | $29.96M | $-83.70M | $-78.66M | $-205.75M | $331.52M | $-393.39M | $127.36M | $59.46M | $10.59M | $-177.99M | $232.97M | $3.69M | $-54.21M |
| Cash at End of Period | $489.80M | $412.19M | $407.30M | $433.33M | $403.97M | $458.31M | $390.48M | $464.50M | $434.54M | $518.24M | $596.91M | $802.66M | $471.13M | $864.52M | $737.16M | $677.70M | $667.12M | $845.10M | $612.13M | $608.44M |
| Cash at Beginning of Period | $412.19M | $407.30M | $433.33M | $403.97M | $457.93M | $390.48M | $464.50M | $434.54M | $518.24M | $596.91M | $802.66M | $471.13M | $864.52M | $737.16M | $677.70M | $667.12M | $845.10M | $612.13M | $608.44M | $662.65M |
| Operating Cash Flow | $124.15M | $163.61M | $97.65M | $69.17M | $81.05M | $97.71M | $98.07M | $98.12M | $90.42M | $7.51M | $50.20M | $46.31M | $157.92M | $230.36M | $154.62M | $113.61M | $284.73M | $135.66M | $92.12M | $62.81M |
| Capital Expenditure | $-42.90M | $-63.64M | $-42.28M | $-40.18M | $-42.24M | $-44.07M | $-34.64M | $-35.73M | $-46.93M | $-24.06M | $-14.26M | $-28.90M | $-43.24M | $-34.63M | $-23.39M | $-19.55M | $-39.13M | $-19.98M | $-18.12M | $-21.69M |
| Free Cash Flow | $81.25M | $99.97M | $55.37M | $29.00M | $38.80M | $53.64M | $63.43M | $62.39M | $43.49M | $-16.55M | $35.94M | $17.42M | $114.68M | $195.74M | $131.24M | $94.06M | $245.60M | $115.69M | $74.01M | $41.12M |
Bio-Rad Laboratories Dividends
Explore Bio-Rad Laboratories's dividend history, including dividend yield, payout ratio, and historical payments.
Bio-Rad Laboratories News
Read the latest news about Bio-Rad Laboratories, including recent articles, headlines, and updates.
BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin and Lower Operating Costs, Offsetting 11% Revenue Decrease Due to Business Transition; Hosts Investor Call Today at 10am ET
BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin & Lower Operating Costs, Offsetting 11% Revenue Decrease From Business Transition.
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year.
Enveric Biosciences Participating in BIO-Europe Spring®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring®, which is being held in Milan, Italy, March 17-19, 2025. During the Spring partnering event, members of Enveric's management team are conducting one-on-one meeting.
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if blue.
BIO-key Partners with California Ed Tech JPA to Make its Identity and Access Management Solutions Available to 195 Member Institutions Serving Over 2.6M Students
BIO-key (BKYI) Partners with California Ed Tech JPA to Make Identity & Access Management Solutions Available to 195 Member Institutions and 2.6M Students.
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025
CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D.
Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Conference Call Participants Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Conor McNamara - RBC Capital Markets Tycho Peterson - Jefferies Operator Thank you for standing by. My name is Prila [ph] and I will be your conference operator today.
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, commented: “Bio-Rad demonstrated resilience and adaptability in 2024. While the biopharma headwinds dampened our Life Science segment results, our Clinical Diagnostics business.
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies (“Stilla”). The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quart.
Oncocyte Prices $29.1 Million Equity Offering
IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”).
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis.
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 10, 2025, at 1:45 p.m. ET in New York City.
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST CARMIEL, Israel , Feb. 4, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott Marquis in New York City. Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 11, 2025 at 10:15 AM EST at the Royale Room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees.
Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference
CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference. The conference will take place February 10-11, 2025, in New York, NY.
Reviva to Participate in the 2025 BIO CEO & Investor Conference
CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY.
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year of 2024 on Thursday, February 13, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 o.
Three Higher Education Customers with 30,000+ Users Migrate to BIO-key's PortalGuard IDaaS Cloud Platform for Streamlined Operations and Enhanced Access Management
BKYI: 3 Higher-Ed Customers with 30,000+ Users Migrate to BIO-key's PortalGuard IDaaS Cloud Platform for Streamlined Operations & Enhanced Access Mgt.
New Jersey Based Biometric and Cyber Security Solutions Provider BIO-key to Present and Participate at DealFlow's Atlantic City Microcap Conference Jan. 29th and 30th
ATLANTIC CITY, NJ and HOLMDEL, NJ / ACCESSWIRE / January 10, 2025 / BIO-key® International, Inc. (NASDAQ:BKYI), an innovative provider of identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless, and phish-resistant authentication, will present and meet with investors at DealFlow Event's Microcap Conference on Wednesday, January 29th & 30th at the Borgata hotel in Atlantic City, New Jersey. CEO Mike DePasquale will present at 2:00pm ET on Wednesday and be available for meetings both days.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for BIO.